These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 17510772)

  • 1. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center.
    Deraco M; Kusamura S; Laterza B; Favaro M; Fumagalli L; Costanzo P; Baratti D
    In Vivo; 2006; 20(6A):773-6. PubMed ID: 17203766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Oliva DG; Laterza B; Deraco M
    Ann Surg Oncol; 2007 Feb; 14(2):500-8. PubMed ID: 17151789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
    Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
    In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Nonaka D; Cabras AD; Laterza B; Deraco M
    Ann Surg; 2009 Feb; 249(2):243-9. PubMed ID: 19212177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei.
    Kusamura S; Hutanu I; Baratti D; Deraco M
    J Surg Oncol; 2013 Jul; 108(1):1-8. PubMed ID: 23720095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
    Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution.
    Chua TC; Yan TD; Smigielski ME; Zhu KJ; Ng KM; Zhao J; Morris DL
    Ann Surg Oncol; 2009 Jul; 16(7):1903-11. PubMed ID: 19387742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC.
    Ross A; Sardi A; Nieroda C; Merriman B; Gushchin V
    Eur J Surg Oncol; 2010 Aug; 36(8):772-6. PubMed ID: 20561764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
    Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence.
    Alexander-Sefre F; Chandrakumaran K; Banerjee S; Sexton R; Thomas JM; Moran B
    Colorectal Dis; 2005 Jul; 7(4):382-6. PubMed ID: 15932563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome.
    Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
    Ann Surg Oncol; 2007 Feb; 14(2):493-9. PubMed ID: 17103067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
    Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
    Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
    In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
    Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.
    Di Fabio F; Aston W; Mohamed F; Chandrakumaran K; Cecil T; Moran B
    Colorectal Dis; 2015 Aug; 17(8):698-703. PubMed ID: 25704482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
    Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S
    Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with pseudomyxoma peritonei.
    Deraco M; De Simone M; Rossi CR; Cavaliere F; Di Filippo F; Vaira M; Piatti P; Kusamura S
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):35-9. PubMed ID: 16767904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Elias D; Honoré C; Ciuchendéa R; Billard V; Raynard B; Lo Dico R; Dromain C; Duvillard P; Goéré D
    Br J Surg; 2008 Sep; 95(9):1164-71. PubMed ID: 18690633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.